JP2022553129A5 - - Google Patents

Info

Publication number
JP2022553129A5
JP2022553129A5 JP2022518775A JP2022518775A JP2022553129A5 JP 2022553129 A5 JP2022553129 A5 JP 2022553129A5 JP 2022518775 A JP2022518775 A JP 2022518775A JP 2022518775 A JP2022518775 A JP 2022518775A JP 2022553129 A5 JP2022553129 A5 JP 2022553129A5
Authority
JP
Japan
Prior art keywords
seq
antigen
binding fragment
humanized antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022518775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553129A (ja
JP7754506B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2020/051082 external-priority patent/WO2021070181A1/en
Publication of JP2022553129A publication Critical patent/JP2022553129A/ja
Publication of JP2022553129A5 publication Critical patent/JP2022553129A5/ja
Priority to JP2025069830A priority Critical patent/JP2025118688A/ja
Application granted granted Critical
Publication of JP7754506B2 publication Critical patent/JP7754506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022518775A 2019-10-08 2020-10-07 ポリオウイルス受容体(pvr)に対する抗体およびその使用 Active JP7754506B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025069830A JP2025118688A (ja) 2019-10-08 2025-04-21 ポリオウイルス受容体(pvr)に対する抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962912534P 2019-10-08 2019-10-08
US62/912,534 2019-10-08
PCT/IL2020/051082 WO2021070181A1 (en) 2019-10-08 2020-10-07 Antibodies against the poliovirus receptor (pvr) and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025069830A Division JP2025118688A (ja) 2019-10-08 2025-04-21 ポリオウイルス受容体(pvr)に対する抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2022553129A JP2022553129A (ja) 2022-12-22
JP2022553129A5 true JP2022553129A5 (enExample) 2023-10-17
JP7754506B2 JP7754506B2 (ja) 2025-10-15

Family

ID=73038283

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022518775A Active JP7754506B2 (ja) 2019-10-08 2020-10-07 ポリオウイルス受容体(pvr)に対する抗体およびその使用
JP2025069830A Pending JP2025118688A (ja) 2019-10-08 2025-04-21 ポリオウイルス受容体(pvr)に対する抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025069830A Pending JP2025118688A (ja) 2019-10-08 2025-04-21 ポリオウイルス受容体(pvr)に対する抗体およびその使用

Country Status (11)

Country Link
US (1) US12570757B2 (enExample)
EP (1) EP4041392A1 (enExample)
JP (2) JP7754506B2 (enExample)
KR (1) KR20220082007A (enExample)
CN (2) CN114502595B (enExample)
AU (1) AU2020363041B2 (enExample)
BR (1) BR112022006620A2 (enExample)
CA (1) CA3156983A1 (enExample)
IL (1) IL291540A (enExample)
MX (1) MX2022004194A (enExample)
WO (1) WO2021070181A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041392A1 (en) * 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
CN118302445A (zh) * 2021-08-20 2024-07-05 塔斯里夫制药有限责任公司 抗cd155抗体和抗原结合片段及其使用方法
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
KR102615797B1 (ko) * 2022-04-28 2023-12-19 가톨릭대학교 산학협력단 T 세포에 의한 교모세포종 치료 효과의 유효성 예측 방법
US20260014268A1 (en) 2022-09-04 2026-01-15 Nectin Therapeutics Ltd. Drug conjugates of humanized anti pvr antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途
EP4585926A1 (de) * 2024-01-09 2025-07-16 Siemens Healthcare Diagnostics Products GmbH Verfahren und kit zur reduzierung von interferenzen in immunoassays

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
WO1995003832A1 (en) 1993-07-30 1995-02-09 Thomas Jefferson University Intracellular immunization
EP0787185A2 (en) 1994-10-20 1997-08-06 MorphoSys AG Targeted hetero-association of recombinant proteins to multi-functional complexes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
US6518033B1 (en) 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1891107B1 (en) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
JP5457671B2 (ja) 2005-07-28 2014-04-02 ノバルティス アーゲー M−csf特異的モノクローナル抗体およびその使用
NZ616992A (en) 2005-12-20 2015-07-31 Sbi Biotech Co Ltd Anti-ilt7 antibody
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
FR2909092B1 (fr) 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
MY149129A (en) 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
JP5686361B2 (ja) 2010-01-28 2015-03-18 国立大学法人 筑波大学 可溶型cd155タンパク質を用いた癌の検出方法
NZ611428A (en) 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
JP6185463B2 (ja) 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Rspo結合剤およびその使用法
EP3202419A1 (en) 2012-06-06 2017-08-09 OncoMed Pharmaceuticals, Inc. Pvrig binding agents that modulate the hippo pathway and uses thereof
HK1210964A1 (en) 2012-12-04 2016-05-13 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
JP6296650B2 (ja) * 2013-03-13 2018-03-20 国立大学法人 筑波大学 免疫疾患に対する医薬組成物
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
KR20160047567A (ko) 2013-08-28 2016-05-02 스템센트알엑스 인코포레이티드 조작된 항-dll3 접합체 및 사용 방법
WO2015051159A1 (en) 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
EP3119211A1 (en) 2014-03-18 2017-01-25 Gokmen, Vural A solution for extending shelf life of ready-to-eat fresh fruits and/or vegetables and an application method thereof
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Tigitに対する抗体
JP5995117B2 (ja) * 2015-01-26 2016-09-21 国立大学法人 筑波大学 可溶型cd155タンパク質を用いた癌の検出方法
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3349792A1 (en) * 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
CA3015619A1 (en) * 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
EP4041392A1 (en) * 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof

Similar Documents

Publication Publication Date Title
JP2022553129A5 (enExample)
JP2020510422A5 (enExample)
ES2609859T3 (es) Composición de fármaco para el tratamiento y/o la prevención del cáncer
US20230287119A1 (en) Anti-cd3 antibody and molecules comprising the antibody
AU2016339832B2 (en) Antibody agents specific for human CD19 and uses thereof
JP2022008382A5 (enExample)
JP7734753B2 (ja) 抗cldn6抗体およびその使用
JP2021508469A5 (enExample)
JP2020525032A5 (enExample)
US9725519B2 (en) Antibody against transporter and use thereof
JP2018532766A5 (enExample)
JP2025118688A5 (enExample)
JP2018504105A5 (enExample)
JP7851923B2 (ja) インターロイキン1アルファに特異的な真のヒト抗体
JP2021515541A5 (enExample)
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
JP7830445B2 (ja) インターロイキン1アルファに特異的な真のヒト抗体
JP2016518333A5 (enExample)
JP2023545183A5 (enExample)
JP2021515542A5 (enExample)
JP2021512652A5 (enExample)
WO2024125667A1 (zh) 一种针对SARS-CoV或SARS-CoV-2的单克隆抗体、其制备方法及应用
JP2026507758A (ja) 抗ccr8抗体とその使用
IL277899B2 (en) Methods and preparations for treating yellow fever
CN110603267A (zh) 与p53-MHC I类复合物结合的T细胞受体样抗体